US FDA grants priority review for new indication for AstraZeneca’s heart attack drug

The US Food and Drug Administration has accepted a supplemental new drug application (sNDA) and granted Priority Review for Anglo-Swedish pharma major AstraZeneca’s (LSE: AZN) Brilinta (ticagrelor) tablets for patients with a history of heart attack.

A Priority Review designation is granted to medicines that the FDA determines have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease. The Prescription Drug User Fee Act goal date will be in the third quarter of 2015. In its current indications, Brilinta generated first-quarter 2015 sales of $131 million, up 32% year-on-year.